Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Metrion Biosciences.

    Client Virtual Booth

    METRION BIOSCIENCES

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Metrion Biosciences
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Suite 1, Riverside 3 Granta Park Great Abington Cambridge CB21 6AD
    Telephone
    Telephone
    +44 (0) 1223 919 100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.metrionbiosciences.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Metrion Biosciences and The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder

    Details:

    Variants of the KCNC1 gene impact Kv3.1 potassion channel function, resulting in neurodevelopmental diorders which can include progressive myolclonic epilepsy (PME) and developmental epileptic encephalopathy (DEE).


    Lead Product(s): Undisclosed

    Therapeutic Area: Genetic Disease Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Small molecule

    Partner/Sponsor/Collaborator: KCNC1 Foundation

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration December 07, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Metrion Biosciences and Bioqube Ventures Collaborate on Venture Creation Project to Identify Novel Ion Channel Inhibitors for Autoimmune Diseases

    Details:

    Under the terms of the collaboration, Bioqube and Metrion will advance a lead series of previously identified highly potent and selective small molecule inhibitors of the human Kv1.3 potassium ion channel to enable further development.


    Lead Product(s): Undisclosed

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Small molecule

    Recipient: Bioqube Ventures

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration December 16, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Sosei Heptares and Metrion Biosciences to collaborate on structure-based drug discovery approaches to ion channels

    Details:

    The collaboration aims to demonstrate the potential of Sosei Heptares’ SBDD technologies to address disease-associated ion channels and work towards establishing a leadership position in this area, in a similar way that it has done for G protein-coupled receptors (GPCRs).


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: Discovery PlatformProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Sosei Heptares

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration February 01, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Metrion Biosciences and LifeArc Further Extend Neuroscience-focused Ion Channel Drug Discovery Collaboration

    Details:

    The collaboration focuses on the discovery of novel selective small molecular modulators of a specific two-pore potassium ion target, identified as likely to be involved in neurological pathogenesis, and has now progressed to the hit-to-lead optimization phase.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: DiscoveryProduct Type: Small molecule

    Partner/Sponsor/Collaborator: LifeArc

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration January 18, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search